NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
University Health Network, Toronto
Deciphera Pharmaceuticals, LLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Canadian Cancer Trials Group
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute